Evidence map›Paper›PMID 38919489›Full record

Observational studyFrontiers in endocrinology2024

Prevalence and co-prevalence of comorbidities among Chinese adult patients with type 2 diabetes mellitus: a cross-sectional, multicenter, retrospective, observational study based on 3B study database.

Qiuhe Ji, Shangyu Chai, Ruya Zhang, Jihu Li, Yiman Zheng, Swapnil Rajpathak

Registry-linked trialAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01128205 (Nationwide Assessment of Cardiovascular Risk Factors), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01128205 completednot on this map

Nationwide Assessment of Cardiovascular Risk Factors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients With Type 2 Diabetes, A Study of China Cardiometabolic Registries (CCMR)

TypeobservationalSponsorChina Cardiometabolic RegistriesRan2010 to 2011Enrolled25,000ConditionsType 2 Diabetes
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qiuhe JiDepartment of Endocrinology and Metabolism, Xi'an International Medical Center Hospital, Shanxi, China.
Shangyu ChaiValue & Implementation Global Medical & Scientific Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, China.
Ruya ZhangValue & Implementation Global Medical & Scientific Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, China.
Jihu LiGovernment Affairs & Market Access, Merck Sharp & Dohme (MSD) China, Shanghai, China.
Yiman ZhengValue & Implementation Global Medical & Scientific Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, China.
Swapnil RajpathakValue & Implementation Outcomes Research, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to investigate the prevalence and co-prevalence of comorbidities among Chinese individuals with type 2 diabetes (T2DM). Methods: Medical records were retrospectively retrieved from the 3B Study database, which provided a comprehensive assessment of comorbid conditions in Chinese adult outpatients with T2DM. Patient characteristics, laboratory measures, and comorbidities were summarized via descriptive analyses, overall and by subgroups of age (<65, 65-74, 75 years) and gender. Results: Among 25,454 eligible patients, 53% were female, and the median age was 63 years. The median time of diabetes duration was 6.18 years. A total of 20,309 (79.8%) patients had at least one comorbid condition alongside T2DM. The prevalence of patients with one, two, three, and four or more comorbid conditions was 28.0%, 24.6%, 15.6%, and 11.6%, respectively. Comorbidity burden increased with longer T2DM duration. Older age groups also exhibited higher comorbidity burden. Females with T2DM had a higher overall percentage of comorbidities compared to males (42.7% vs. 37.1%). The most common comorbid conditions in T2DM patients were hypertension (HTN) in 59.9%, overweight/obesity in 58.3%, hyperlipidemia in 42.0%, retinopathy in 16.5%, neuropathy in 15.2%, cardiovascular disease (CVD) in 14.9%, and renal disease in 14.4%. The highest co-prevalence was observed for overweight/obesity and HTN (37.6%), followed by HTN and hyperlipidemia (29.8%), overweight/obesity and hyperlipidemia (27.3%), HTN and CVD (12.6%), HTN and retinopathy (12.1%), and HTN and renal disease (11.3%). Conclusion: The majority of T2DM patients exhibit multiple comorbidities. Considering the presence of multimorbidity is crucial in clinical decision-making. Systematic review registration: https://clinicaltrials.gov/, identifier NCT01128205.

Indexed as

ComorbidityDiabetes Mellitus, Type 2AdultAgedChinaCross-Sectional StudiesDatabases, FactualEast Asian PeopleFemaleHumansHypertensionMaleMiddle AgedPrevalenceRetrospective Studies3B studycomorbidityco-prevalenceprevalencetype 2 diabetes

Identifiers

PMID38919489
PMCPMC11196810

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.